APR = 5 2002
: SECTION 10 7
siok) summary K OAQD T
oc
This 510(k) summary of safety and effectiveness for the Viridis Derma (frequency doubled
Nd:YAG) laser is submitted in accordance with the requirements of SMDA 1990 and follows
Office of Device Evaluation guidance concerning the organization and content of a 510(k)
summary.
Applicant: QUANTEL MEDICAL
Address: QUANTEL MEDICAL
21 rue Newton
ZI du BREZET
63039 Clermont-Ferrand
Cedex 2
FRANCE
+33 (0)473 745 745
+33 (0)473 745 700 (Fax)
Contact Person: Mr. Jean Abascal
Regulatory Affairs Manager
; (+33) 169 29 17 25 .
(433) 169 29 17 29 (Fax)
Preparation Date: December 2001
(of the Summary)
Device Name: Viridis Derma ,
Common Name: Frequency Doubled Nd:YAG Surgical Laser
Classification: Laser surgical instrument for use in general and plastic surgery and in
Name: _ dermatology (see: 21 CFR 878.4810).
Product Code: GEX
Panel: 79
iat al |
Predicate device! The Viridis Laser (K001784): Nuvo-Lase 660 Laser System (K970667)
| | COMPACT KTP Laser (K983020), DioLite 532 Laser System (K964074),
Nidek Dio-Lite 60 Laser System (K981447), Altus Family of CoolGlide
Aesthetic Lasers (K003202)
Device desertion: The Viridis Derma frequency doubled Nd:YAG laser emits a beam of
| eoherent light at 532 microns.
| 7 040
Jl i

Indications: The Viridis Derma laser is intended for photocoagulation of pigmented
lesions in dermatology.
These include the following applications:
Benign Vascular Lesions Facial Telangiectasias
Port Wine Stains Café au-lait
Erythrosis Benign Pigmented Lesions
Cuperosis Senile Lentigo
Keratoses Hemangiomas (spider and cherry/
Dermatosis Papulosis Nigra (DPN) _ strawberry)
Leg Telangiectasia - only as a complement to sclerotherapy and for small
superficial red vessels
The Viridis Derma laser will be labeled as a prescription device as follows:
CAUTION: Federal (US) law restricts the use of this device to licensed professionals
Performance Data: None required.
CONCLUSION:
Based on the information in the notification Quantel Medical concludes that the Viridis
Derma frequency doubled Nd:YAG laser is substantially equivalent to the Viridis laser and :
to other cited legally marketed predicates, under the conditions of intended use (above).
04i

re . :
e Le DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
“ona — : / : Food and Drug Administration
Lo ; . / -- 9200 Corporate Boulevard:
: Rockville MD 20850
. Quantel Medical oe , : a
c/o Mr. Roger W. Barnes
342 Sunset Bay Road APR = 5 2002
Hot Springs, AR 71913
Re: K020071
Trade/Device Name: Viridis Derma Laser
Regulation Number: 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II :
: Product Code: GEX
Dated: January 7, 2002
Received: January 9, 2002
Dear Mr. Barnes:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class Il (Special Controls) or class IIT (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CER Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

. , > Page 2 Mr: Roger W. Barnes SO 7
_ This letter will allow you to begin marketing your device as described in your Section 510(k)
'. _premarket notification. The FDA finding of substantial equivalence of your device to a legally oo
_ marketed predicate device results in a classification for your device and thus, permits your device’

to proceed to the market. : If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and
additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of
Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of
your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the
regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97).
Other general information on your responsibilities under the Act may be obtained from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 443-6597 or at its Internet address
http://www. fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Puan € Provnt
(Celia M. Witten, Ph.D. MD.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
; Radiological Health

Enclosure

a SECTIONT =
_ INDICATIONS FOR USE STATEMENT -_
a 510(k) Number (if known): JO QAOOT{
Device Name:_Viridis Derma (Frequency doubled Nd:YAG laser ,
Indications for Use Statement:
The Viridis Derma laser is intended for photocoagulation of pigmented lesions in
dermatology.
These include the following specific applications:
Benign Vascular Lesions Facial Telangiectasias
Port Wine Stains Café au-lait
Erythrosis Benign Pigmented Lesions
Cuperosis Senile Lentigo
Keratoses Hemangiomas (spider and cherry/
Dermatosis Papulosis Nigra (DPN) strawberry)
Leg Telangiectasia - only as a complement to sclerotherapy and for small superficial
red vessels
The Viridis Derma laser is labeled as a prescription device as follows:
CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician.
Nuon frevert
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices
510(k) Number_K C26 O7 .
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
. Concurrence of CDRH, Office of Device Evaluation
Prescription Use NK. OR Over-The Counter Use __
(Per 21 CFR 801.109)
_ O37
|

